The Neurodegeneration Revolution

Dr. Trideva Sastri Koduru, Ph.D., currently holds a faculty position in the Department of Pharmaceutics at JSS College of Pharmacy, JSS Academy of Higher Education & Research in Mysuru, Karnataka, India. His doctoral research was a pioneering exploration into miRNA-based therapies for managing Multiple Sclerosis, garnering recognition through a Senior Research Fellowship from the Innovation and Translation Research division of the Indian Council of Medical Research (ICMR), New Delhi, India. His work published in journals of international repute, including Drug Discovery Today, Dr. Sastri's research explores into nanoscience-aided drug carrier systems and the genetic intricacies of autoimmune conditions. His dedication extends to developing efficient carrier systems for delivering nucleic acid therapies, mainly focused on neurological conditions. Dr. Sastri envisions a future characterized by continued research in drug delivery systems. His forthcoming endeavors center on crafting highly efficient, targeted carrier systems for delivering miRNA therapeutics, contributing substantially to the progressive landscape of pharmaceutical sciences. Dr. Riyaz Ali M Osmani, Ph.D., completed his graduation and post-graduation in Pharmacy from Shivaji University, Kolhapur, followed by his Doctoral Research from JSS Academy of Higher Education and Research (JSS AHER), Mysuru. He continued his Postdoctoral Research at Department of Biosciences and Bioengineering (BSBE), Indian Institute of Technology Bombay (IITB), Mumbai, India, and later also served as a Project Research Scientist at the same Department. Till date, to his credit he has more than 157 research publications in numerous National and International journals of repute (with cumulative IF>350), and has authored many book chapters as well as review articles. Moreover, he is the reviewer of many esteemed, peer-reviewed journals. He has been conferred with various awards and honors for his scientific contributions and services. He is an active member of Indian Pharmaceutical Association (IPA), and life member of Indian Pharmaceutical Graduate Association (IPGA) and Association of Pharmaceutical Teachers of India (APTI). Furthermore, he has many achievements and recognitions at every level of curriculum. He is currently working as an Assistant Professor at the Department of Pharmaceutics, JSS College of Pharmacy, JSS AHER, Mysuru. His research interests include pharmaceutics, pharmaceutical nanotechnology, nanomedicine, pre-formulation profiling, solid state characterization, nanomaterials, microneedles technology, polymer grafting etc., to name a few. Despite nanotechnology and nanomedicines being vast research meadows; he takes special interest in developing nanocarriers based novel drug delivery systems for a range of ailments. Dr. Ekta Singh, Ph.D., pursued her PhD in biomedical engineering from IIT Bombay, where her research was focused on developing trigger-responsive theranostics for Rheumatoid Arthritis and is currently placed as a postdoctoral research scientist with Prof. Michael P Sheetz at UTMB Galveston. Dr Singh’s current research is focused on paracrine factors secreted by normal human fibroblasts when treated with Low-frequency Ultrasound (LFU). What makes these molecules exciting and worth exploring is that these secretory factors have the potential to rejuvenate senescent fibroblasts—furthermore, study the long-term effects of LFU on the glucose metabolism in old high-fat diabetic mice. The study's preliminary findings indicate an improved oral glucose tolerance and insulin response after LFU treatment. Additionally, her study explores the effects of mechanical stimulation via LFU on total thickness cutaneous wound healing in old mice. Being in her early research transition phase, Dr Singh is curious to learn what novel insights her research group would unveil towards mechanotherapy. She is an aspiring academician interested in developing new teaching designs and effective mentorship. When she is not with her micropipette and books, she loves playing her Ukulele. Besides, she is very fond of travelling to countryside locations and taking photos of food. Dr. Suman Dutta, Ph.D., is a Research Scientist at the Nuffield Department of Clinical Neurosciences, University of Oxford, UK. He began his research career studying inflammation-induced macrophage apoptosis, leading to the attainment of a Ph.D. from India. Currently, he researches the potential of brain-derived blood extracellular vesicles as biomarkers for neurodegenerative diseases, with a focus on identifying cell-specific extracellular vesicle markers. Dr. Dutta's expertise in extracellular vesicle biology was developed through previous positions at renowned institutions including the University of California Los Angeles, USA. Throughout his career, he has made significant contributions to the field of extracellular vesicles and neurodegenerative disorders. Committed to the scientific community, he actively contributes through publications, presentations, journal editing, and peer review

• Section 1: Neurodegeneration and Basics1. Introduction to Neurodegeneration2. Mechanisms of Neurodegeneration3. Risk Factors and Genetic Predisposition4. Diagnosis and Management of Neurodegenerative DiseasesSection 2: Established Therapies for Managing Neurodegeneration5. Current Pharmacological Treatments6. Non-Pharmacological Therapies7. Nutritional Interventions8. Lifestyle Changes for Neurodegeneration Prevention andManagementSection 3: Advanced Therapies and Novel - New Age Delivery Systems9. Gene Therapy for Neurodegeneration10. Stem Cell Therapy for Neurodegeneration11. Nanoparticle-Mediated Drug Delivery for NeurodegenerativeDiseases12. Exosomes and Extracellular Vesicles for NeurodegenerativeDiseasesSection 4: Sustainable Green Nanotechnology and Integration of AI/ML forDeveloping Nano Carriers13. Sustainable green nanotechnology and its potentialfor developing nanocarriers for neurodegenerative diseases14. AI/ML in the development of nanocarriers15. Benefits of integrating sustainable green nanotechnology and AI/ML for the development of nanocarriers.16. Challenges and ethical considerationsSection 5: Emerging Frontiers in Neurodegenerative Disease Management17. Biomarker research for neurodegenerative diseases18. Ethical and social implications of managing neurodegenerative diseases19. Caregivers and the management of neurodegenerative diseases20. Global burden of neurodegenerative diseasesSection 6: Clinical Trials and Recent Research, Future Directions, and Conclusion21. Clinical Trials for Neurodegenerative Diseases22. Recent Research in Neurodegenerative Diseases23. Future Directions for Neurodegenerative Disease Management24. Conclusion: Challenges and Opportunities in NeurodegenerativeDiseases Management